Company Profile
Our operations are headquartered in Phillipsburg, NJ. We currently occupy approximately 20,000 sq. ft. of fully equipped laboratory, animal facility, and office space. We currently have 23 full-time employees in both the U.S. and U.K. Fully 30% of these employees hold advanced degrees (PhD, MD, MBA, other) in science and/or business.
Celldex Overview
Celldex is an innovative biotechnology company focused on the discovery, development and commercialization of targeted immunotherapies. Our core focus includes the use of tumor-specific targets and human monoclonal antibodies as precision delivered therapeutic agents for the treatment of cancer, infectious diseases and immune system disorders through our novel 'active immunization' approach. We have developed our Antigen Presenting Cell Targeting Technology (APC Targeting Technology™) that utilizes proprietary human monoclonal antibodies to directly target specialized types of immune system cells known as antigen presenting cells, or APCs - particularly dendritic cells. We are using this technology approach to build a substantial pipeline of clinical development candidates that will address significant gaps in the treatment of many specific cancers, as well as within our growing activities in infectious disease and auto-immune disorders.
Our lead development candidate (CDX-110) is a proprietary phase II development program that has already shown promising results for patients with newly diagnosed malignant glioblastoma, a particularly aggressive form of brain cancer. We believe this product candidate may offer a substantial opportunity for improved survival in these patients, and we intend to initiate a randomized phase II / III clinical trial in early 2007 to provide definitive data with which to file for global marketing approval. In addition, two other phase I clinical trials are on-going in cancer patients with CDX-1307, our initial product candidate based on our APC Targeting Technology™.
Celldex has a highly experienced management team to implement our near- and long-term objectives of advancing our pre-clinical and clinical development programs through late-stage development, at which time we intend to identify optimal commercialization partners to market our products. Celldex is backed by blue-chip venture and institutional investors, and will continue to explore synergistic partnerships to enhance our clinical, research and commercial opportunities.
